The book "Development of a new microparticle vaccine adjuvant, MIS416" by Francesco Mainini provides a comprehensive investigation of a novel vaccine adjuvant derived from the cell wall skeletons of Propionibacterium acnes. MIS416 contains naturally occurring ligands capable of inducing an effective adaptive immune response. This research explores the therapeutic potential of MIS416-adjuvanted vaccines through the direct conjugation of specific peptides derived from tumor-associated antigens (TAA) as well as siRNAs. This allows for the simultaneous delivery of antigen and adjuvant. The results demonstrate that dendritic cells (DC) are activated by the MIS416-peptide conjugate, as evidenced by the analysis of surface markers such as MHCII, CD40, CD80, and CD86. This work represents a significant advancement in vaccine research and provides valuable insights into the development of more effective vaccination strategies.